Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Covid19SARS-CoV Infection
Interventions
DRUG

Placebo

Placebo administered on Days 1-5

DRUG

DuACT

Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID

Trial Locations (1)

Unknown

Sunnyside Office Park, Johannesburg

All Listed Sponsors
collaborator

SynaVir

INDUSTRY

lead

University of Witwatersrand, South Africa

OTHER